Canavan Disease 2012
Coming soon. Until then, go read some poetry!
When spring unfolds the beechen leaf, and sap is in the bough
when light is on the wild-wood stream, and wind is on the brow
when stride is long, and breath is deep, and keen the mountain air
come back to me! Come back to me! And say my land is fair.
The Canavan Disease is a rare genetic, degenerate disorder of the brain. It is always fatal, with patients dying after weeks or the first decades of their life, depending on the type of Canavan disease. Other names or descriptions include spongy degeneration of the brain or Aspartoacylase deficiency.
It is named after Myrtelle Canavan, who described the Disease for the first time in 1931. (http://www.morbus-canavan.com/canavansdisease.htm)
Up to now, there is no final cure for Canavan Disease and treatment mainly focuses on managing the symptoms.
Canavan disease is officially classified as a "rare disease" by the Office of Rare Diseases (ORD) of the National Institutes of Health (NIH). In this classification rare diseases mean to affect less than 200,000 people in the US population.(http://rarediseases.info.nih.gov/RareDiseaseList.aspx)
Yet Canavan disease appears more often in certain ethnic groups of eastern and central European Jewish descent. Out of these Jewish communities, the Ashkenazi Jews form the largest community. Today they account for approximately up to 80 percent of Jews worldwide. 1 per 6,400 - 13,500 people of Ashkenazi Jewish community in the US suffer from Canavan disease and 2% of the Ashkenazi are carriers of Canavan disease, which means that 1 out of 40 persons carriers a mutated allele.
Phenotype: Signs and symptoms
Typical symptoms that occur in Canavan patients after the first weeks of life include:
- macrocephaly (abnormally large head)
- limited motoric abilities that decrease as the disease progresses. These include:
- not being able to crawl, sit, walk, or talk
- weak neck muscles that cause poor head control
- hypotonia in general
- mental retardation
- abnormal muscle tone (e.g., stiffness or floppiness)
These symptoms may be followed by:
- hypotonia leading to paralysis
Classification and Types
With respect to Canavan disease, the dysfunction of white matter expresses as a spongy degeneration and a swelling of glial cells.
Biochemical disease mechanism
The example protein is involved in the example pathway...
Ideally, include a graphical pathway representation like this one:
(see above: own words, no plagiarism)
- link to KEGG
- link to MetaCyc
... see databases in "resources"
- > 50 bekannt. omim und entrez fuer (neutrale) muts
Current knowledge about mutations associated with the disease. - Separate into disease causing and neutral mutations. -- These sequence pages will be the starting point for collecting prediction results and result discussions.
Note: Until further notice you only need to care about the reference sequence pages. -- At a later stage we will assign mutations we expect you to work on. Then, it will make sense to create on page per mutation that is assigned to you.
Which sequence does not cause the disease and is most often found in the population.
Disease causing mutations
Effect of mutations
siehe folien, die armen axons ohne myelin
- prenatal: NAA, mut ana
- postnatal: NAA, neuroimg, mut ana
NAA urine war irgendeine Chromatographie, nur kurz erwähnen oder beim echten wikipedia verlinken